Walbert Timothy P 4

What Happened
Timothy P. Walbert, a director of Mirum Pharmaceuticals (MIRM), had 3,977 restricted stock units (RSUs) convert into common stock on May 29, 2026 (reported as exercise/conversion, code M). The filing shows an acquisition/conversion of 3,977 shares and a simultaneous disposition of 3,977 shares at $0.00. No cash proceeds or purchase price are reported.

Key Details

• Transaction date: May 29, 2026; Form 4 filed June 2, 2026 (timely filing).
• Acquisition: 3,977 shares via conversion/exercise of a derivative (code M); price listed as N/A.
• Disposal: 3,977 shares disposed at $0.00 (listed as a derivative disposition).
• Shares owned after transaction: not disclosed in the provided filing excerpt.
• Footnotes: F1 — each RSU represents a contingent right to one share (or cash equivalent at issuer's discretion). F2 — the RSUs vested on May 29, 2026.
• No 10b5-1 plan or late filing flags noted in the report.

Context
This appears to be a routine vesting/conversion of RSUs rather than an open-market buy or a cash sale; the simultaneous disposition at $0.00 typically reflects withholding/settlement associated with RSU vesting (no cash proceeds reported). Such transactions are common for compensation vesting and do not alone indicate the insider’s market view.